ClinicalTrials.gg
RecruitingNCT07516132Updated Jul 1, 2026

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

A Phase 3 interventional study of OTX-TKI in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by Ocular Therapeutix, Inc.. Recruiting at 8 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
850
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
26th of 491
850 · median 55
Started
2026
with 27 others
Phase 3
86 of 645
8 open now
Primary completion
2030-08
later than 114 of 124 live
Registered
628th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 26th largest by planned enrollment of the 491 interventional ones that give a count, is one of 28 that started in 2026, is one of 86 in phase 3, reaches primary completion later than 114 of the 124 other live ones, and was the 628th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)

Keywords

  • Neovascular Age-Related Macular Degeneration
  • Tyrosine Kinase Inhibitor
  • OTX-TKI
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of nAMD in the study eye who successfully completed Study OTX-TKI-2023-AMD-301 through Week 104 or Study OTX-TKI-2023-AMD-303 through Week 96
  • Have adequate ocular media and adequate pupillary dilation in the study eye to permit good quality fundus imaging
  • Are able and willing to comply with all study requirements and visits
  • Have provided written

Exclusion criteria

Exclusion Criteria:

  • Have significant intraocular or periocular infection (bacterial, viral, or fungal) in the study eye within 3 months prior to Day 1
  • History of intraocular inflammation in the study eye
  • Have evidence of a rhegmatogenous retinal detachment or visually significant/severe epiretinal membrane, macular hole, tear of the retinal pigment epithelium in the macula, or other macular
  • Presence of an intercurrent illness or condition that in the opinion of the Investigator, may place the participant at an unacceptable risk, preventing the participant from completing the study or confound the interpretation of study results
  • Female participants who are pregnant (had a positive urine test at the Baseline visit [Day 1]) or breastfeeding or intend to become pregnant during the study, who are unwilling to use 2 forms of highly effective from baseline until they exit the study or at least 3 months after the last study treatment, whichever is later.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    OTX-TKI

    Drug: OTX-TKI

Interventions

  • Intravitreal Injection of OTX-TKI

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144

    Number of events

    Time frame: from Baseline (Day 1) through Week 144

  2. Proportion of participants with severe vision loss (defined as ≥ 30 Early Treatment Diabetic Retinopathy Study [ETDRS] letters loss) from Baseline (Day 1) through Week 144

    Percentage

    Time frame: from Baseline (Day 1) through Week 144

07

Study locations

8 of 8 sites recruiting
  • California Retina Consultants (CRC)
    Bakersfield, California 93309, United States
    Recruiting
  • California Retina Consultants (CRC)
    Santa Barbara, California 93103, United States
    Recruiting
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
    Recruiting
  • Retina Group of Florida - Fort Lauderdale
    Fort Lauderdale, Florida 33308, United States
    Recruiting
    • Eduardo Uchiyama, MD · Contacteuchiyama@rgfla.com · 954-776-6800
    • Eduardo Uchiyama, MD · Principal investigator
  • Cumberland Valley Retina Associates
    Hagerstown, Maryland 21740, United States
    Recruiting
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
    Recruiting
  • Palmetto Retina Center
    West Columbia, South Carolina 29619, United States
    Recruiting
  • Austin Retina Associates
    Austin, Texas 78705, United States
    Recruiting
    • Robert William Wong, MD · Contact512-451-0103
    • Robert William Wong, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2030, 51 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 51 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Aug 1, 2030
CompletionEst.
Aug 1, 2030
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07516132
Collaborators
Fortrea, Duke Reading Center
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Apr 27, 2026
Primary completion
Aug 1, 2030 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Jul 1, 2026

Study contacts

Clinical Project Manager
Contact
clinicalaffairs@ocutx.com
781-357-4000
Nichole Wilkes
Contact
nwilkes@ocutx.com
770-375-1020
Dilsher Dhoot, MD
principal investigator · California Retina Consultants (CRC)-Bakersfield

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion